Silexion Therapeutics removes director Ilan Levin

Silexion Therapeutics Corp reported a boardroom change, noting that its Board of Directors removed Ilan Levin from his role as a director, effective immediately on March 25, 2026.

Accepted by SEC EDGAR 03/25/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Silexion Therapeutics Corp reported a boardroom change, noting that its Board of Directors removed Ilan Levin from his role as a director, effective immediately on March 25, 2026. The remaining board members acted unanimously by written determination under Article 28.7 of the company’s Amended and Restated Articles of Association.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Silexion Therapeutics (SLXN) disclose?

Silexion Therapeutics disclosed that its Board of Directors removed Ilan Levin as a board member, effective immediately. The decision was taken by a unanimous written determination of all other directors under the company’s Amended and Restated Articles of Association.

When did Silexion Therapeutics (SLXN) remove director Ilan Levin?

The removal of director Ilan Levin from the Silexion Therapeutics board was effective on March 25, 2026. The company’s Board of Directors documented the action that same day through a unanimous written determination by all remaining board members.

Who authorized the removal of Ilan Levin from Silexion Therapeutics’ board?

All remaining members of Silexion Therapeutics’ Board of Directors authorized the removal of Ilan Levin. They acted unanimously by written determination, following Article 28.7 of the company’s Amended and Restated Articles of Association governing board decisions and procedures.

What governance provision did Silexion Therapeutics (SLXN) rely on to remove Ilan Levin?

The board relied on Article 28.7 of Silexion Therapeutics’ Amended and Restated Articles of Association. This provision allowed all other directors to adopt a unanimous written determination effecting the immediate removal of Ilan Levin as a member of the Board of Directors.

What type of SEC filing reported Silexion Therapeutics’ board change?

The board change at Silexion Therapeutics was reported in a Form 8-K. This current report form is used to disclose significant corporate events, including changes in directors or certain officers and related corporate governance developments at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000202241600-0000000972NASDAQNASDAQ00020224162026-03-252026-03-250002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2026-03-252026-03-250002022416slxn:OrdinarySharesParValue00135PerShareMember2026-03-252026-03-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 25, 2026

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-756-4999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) Removal of Director

On March 25, 2026, the Board of Directors (the “Board”) of Silexion Therapeutics Corp (the “Company”) removed Ilan Levin from his position as a member of the Board, effective immediately. The removal was effected via a unanimous determination adopted by all other members of the Board in writing pursuant to Article 28.7 of the Company’s Amended and Restated Articles of Association, as amended.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: March 25, 2026	By: /s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 17.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 27.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 20.0 KB